Kala Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About Kala Pharmaceuticals, Inc.

KALA BIO, Inc. (NASDAQ: KALA), formerly Kala Pharmaceuticals, Inc., is a United States-based biopharmaceutical company listed on the NASDAQ market in the United States. Incorporated in 2009 and headquartered in Arlington, Massachusetts, the company is best viewed by French-speaking investors as a small-cap biotech with a highly event-driven risk profile. Its valuation and narrative have historically been driven less by recurring commercial revenues than by clinical milestones, regulatory outcomes, capital raises, and strategic repositioning. KALA’s original focus was ophthalmology, specifically rare and severe diseases affecting the front and back of the eye. The company previously developed and commercialized eye-disease products, but it sold its commercial business to Alcon in 2022. That transaction significantly changed the investment case: KALA moved away from being a commercially oriented ophthalmology platform and toward a more research-intensive, development-stage company centered on proprietary scientific assets and pipeline optionality. The company’s lead therapeutic candidate had been KPI-012, a mesenchymal stem cell secretome-based program aimed at severe corneal-surface disorders, including persistent corneal epithelial defects. In September 2025, KALA stated that the CHASE trial did not meet its primary endpoints, and it subsequently discontinued development of KPI-012 and its MSC-S platform. This was a major setback, but also a catalyst for a broader strategic reset. Since then, management has been exploring alternatives for its legacy assets while pivoting toward a new AI-enabled biotechnology strategy. A notable recent development came in March 2026, when KALA entered into an exclusive license agreement for the Researgency AI research platform. The company described this as the basis for evaluating a dedicated AI infrastructure offering for biotechnology research, with the aim of helping companies unlock value from biological data without giving up control of it. For investors, this suggests a fundamental transformation in business model, from clinical-stage ophthalmology biotech toward an AI-oriented biotech research platform. From a competitive standpoint, KALA operates in an industry dominated by larger pharmaceutical companies, better-capitalized specialty biotechs, and established ophthalmology players. Its competitive edge, if any, is not scale but intellectual property, scientific know-how, and the ability to reposition an under-optimized asset base into a new market niche. That said, the company remains constrained by limited resources, and its future success depends heavily on execution, funding discipline, and the market’s willingness to underwrite a new strategy. Recent news has been material: the failure of a key clinical trial, the discontinuation of a core program, workforce reductions, financing activity, and the launch of a new AI-related strategic initiative. In other words, KALA is no longer just an ophthalmology development story; it is a transition story on NASDAQ in the United States, with high uncertainty but also potentially high optionality if the new direction gains traction.